HRP20131083T1 - POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI - Google Patents
POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI Download PDFInfo
- Publication number
- HRP20131083T1 HRP20131083T1 HRP20131083AT HRP20131083T HRP20131083T1 HR P20131083 T1 HRP20131083 T1 HR P20131083T1 HR P20131083A T HRP20131083A T HR P20131083AT HR P20131083 T HRP20131083 T HR P20131083T HR P20131083 T1 HRP20131083 T1 HR P20131083T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- prepared
- accordance
- intended
- administration
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 230000002062 proliferating effect Effects 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 2
- 239000004202 carbamide Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 2
- 229950010895 midostaurin Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- -1 CT-52923 Chemical compound 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960000435 oblimersen Drugs 0.000 claims 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Spoj Formule I:
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat, namijenjen upotrebi postupku liječenja akutne mijeloidne leukemije kod čovjeka,
naznačen time što se postupak sastoji u primjeni spoja u količini od otprilike 18, otprilike 20, otprilike 25, otprilike 27, otprilike 30, otprilike 35, otprilike 40, otprilike 45, otprilike 50, otprilike 55, otprilike 60, otprilike 90, otprilike 135, otprilike 200, otprilike 300 ili otprilike 450 mg dnevno, gdje akutna mijeloidna leukemija recidivira ili ne reagira na ili je otporna na lijekove.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se spoj pripravlja za intermitentnu primjenu; ili što se spoj pripravlja za kontinuiranu primjenu.
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je spoj dihidrokloridna sol.
4. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se spoj pripravlja za dodatnu primjenu uz drugo terapijsko sredstvo; protutumorsko sredstvo, koje se bira iz skupine koju čine adriamicin, busulfan, citarabin, ciklofosfamid, deksametazon, fludarabin, fluoruracil, hidroksiurea, interferoni, oblimersen, derivati platine, taksol, topotekan i vinkristin; ili inhibitor FLT3 kinaze, koji se bira iz skupine koju čine PKC 412, MLN 578, CEP-701, CT 53518, CT-53608, CT-52923, D-64406, D-65476, AGL-2033, AG1295, AG1296, KN-1022, PKC-412, SU5416, SU5614, SU11248, L-00021649 i CHIR-258.
5. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se spoj pripravlja za primjenu na čovjeku koji je prošao korak dijagnosticiranja radi određivanja prisutnosti konstitutivno aktiviranog mutanta FLT3.
6. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se spoj pripravlja za oralnu, parenteralnu ili intravensku primjenu.
7. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se spoj pripravlja za primjenu jednom dnevno u trajanju od tjedan dana, dva tjedna ili tri tjedna.
8. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se spoj pripravlja za primjenu jednom dnevno u trajanju od četrnaest dana.
9. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se spoj pripravlja za primjenu u režimu doziranja, gdje nakon primjene slijedi period mirovanja, tijekom kojeg se spoj ne primjenjuje, gdje izborno period mirovanja traje jedan, dva, tri, četiri, pet, šest ili sedam dana, ili dva, tri ili četiri tjedna.
10. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se spoj pripravlja za primjenu na čovjeku koji nije liječen protutumorskom terapijom za proliferativnu bolest prije primjene spoja.
11. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se spoj pripravlja za primjenu na čovjeku koji je liječen protutumorskom terapijom za proliferativnu bolest prije primjene spoja.
12. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se akutna mijeloidna leukemija može pripisati mutaciji FLT3 unutarnjom duplikacijom jednom iza druge (ITD).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US258307P | 2007-11-08 | 2007-11-08 | |
| US580307P | 2007-12-07 | 2007-12-07 | |
| US9867608P | 2008-09-19 | 2008-09-19 | |
| US11206008P | 2008-11-06 | 2008-11-06 | |
| PCT/US2008/012539 WO2009061446A1 (en) | 2007-11-08 | 2008-11-07 | Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131083T1 true HRP20131083T1 (hr) | 2013-12-20 |
Family
ID=40262072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131083AT HRP20131083T1 (hr) | 2007-11-08 | 2013-11-13 | POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7968543B2 (hr) |
| EP (2) | EP2596795A1 (hr) |
| JP (2) | JP5645667B2 (hr) |
| KR (2) | KR20150105494A (hr) |
| CN (1) | CN101835472A (hr) |
| AR (1) | AR069244A1 (hr) |
| AU (1) | AU2008325141B2 (hr) |
| CA (1) | CA2696807C (hr) |
| CY (1) | CY1114853T1 (hr) |
| DK (1) | DK2205244T3 (hr) |
| ES (1) | ES2436266T3 (hr) |
| HR (1) | HRP20131083T1 (hr) |
| MX (1) | MX2010002396A (hr) |
| PL (1) | PL2205244T3 (hr) |
| PT (1) | PT2205244E (hr) |
| SI (1) | SI2205244T1 (hr) |
| TW (1) | TW200924756A (hr) |
| WO (1) | WO2009061446A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101448843B (zh) * | 2006-03-17 | 2012-05-09 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
| BRPI0816904B8 (pt) | 2007-09-19 | 2021-12-07 | Ambit Biosciences Corp | Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida |
| CA2755976C (en) | 2009-03-23 | 2020-04-07 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| US8865710B2 (en) * | 2009-05-14 | 2014-10-21 | Ambit Biosciences Corporation | Methods of treating proliferative diseases |
| EP2496584B1 (en) | 2009-11-05 | 2016-09-21 | Ambit Biosciences Corporation | Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives |
| WO2011083124A1 (en) | 2010-01-05 | 2011-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
| JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| CN104513252B (zh) * | 2013-09-26 | 2017-11-10 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| US10065937B2 (en) | 2014-07-31 | 2018-09-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | FLT3 receptor antagonists |
| CA2971861C (en) | 2014-12-22 | 2024-02-13 | Genzyme Corporation | Methods of culturing a mammalian cell |
| CA2976752C (en) | 2015-02-20 | 2019-12-17 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
| JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| KR20200013683A (ko) | 2017-05-17 | 2020-02-07 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 오피오이드에 의한 통증 치료 개선용 ｆｌｔ3 저해제 |
| CN113966331B (zh) * | 2020-03-11 | 2024-04-12 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233906A (en) * | 1880-11-02 | Combined stirrer and thermometer | ||
| US233903A (en) * | 1880-11-02 | Velocipede | ||
| US994635A (en) * | 1911-01-10 | 1911-06-06 | Harry C Buhoup | Car-truck. |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| CN101448843B (zh) * | 2006-03-17 | 2012-05-09 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
| BRPI0816904B8 (pt) * | 2007-09-19 | 2021-12-07 | Ambit Biosciences Corp | Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida |
-
2008
- 2008-11-07 MX MX2010002396A patent/MX2010002396A/es active IP Right Grant
- 2008-11-07 DK DK08847113.1T patent/DK2205244T3/da active
- 2008-11-07 ES ES08847113T patent/ES2436266T3/es active Active
- 2008-11-07 EP EP12197285.5A patent/EP2596795A1/en not_active Withdrawn
- 2008-11-07 PL PL08847113T patent/PL2205244T3/pl unknown
- 2008-11-07 CA CA2696807A patent/CA2696807C/en active Active
- 2008-11-07 AU AU2008325141A patent/AU2008325141B2/en active Active
- 2008-11-07 TW TW097143281A patent/TW200924756A/zh unknown
- 2008-11-07 SI SI200831093T patent/SI2205244T1/sl unknown
- 2008-11-07 US US12/267,321 patent/US7968543B2/en active Active
- 2008-11-07 EP EP08847113.1A patent/EP2205244B1/en active Active
- 2008-11-07 WO PCT/US2008/012539 patent/WO2009061446A1/en active Application Filing
- 2008-11-07 PT PT88471131T patent/PT2205244E/pt unknown
- 2008-11-07 AR ARP080104899A patent/AR069244A1/es unknown
- 2008-11-07 KR KR1020157024194A patent/KR20150105494A/ko not_active Application Discontinuation
- 2008-11-07 KR KR1020107006419A patent/KR101578481B1/ko active IP Right Grant
- 2008-11-07 JP JP2010533098A patent/JP5645667B2/ja active Active
- 2008-11-07 CN CN200880112433A patent/CN101835472A/zh active Pending
-
2013
- 2013-11-13 HR HRP20131083AT patent/HRP20131083T1/hr unknown
- 2013-11-21 CY CY20131101036T patent/CY1114853T1/el unknown
-
2014
- 2014-06-11 JP JP2014120238A patent/JP2014221765A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20090123418A1 (en) | 2009-05-14 |
| JP5645667B2 (ja) | 2014-12-24 |
| PL2205244T3 (pl) | 2014-01-31 |
| CA2696807C (en) | 2017-11-28 |
| CY1114853T1 (el) | 2016-12-14 |
| EP2205244A1 (en) | 2010-07-14 |
| KR20150105494A (ko) | 2015-09-16 |
| DK2205244T3 (da) | 2013-11-25 |
| TW200924756A (en) | 2009-06-16 |
| AU2008325141A1 (en) | 2009-05-14 |
| JP2011503063A (ja) | 2011-01-27 |
| KR101578481B1 (ko) | 2015-12-17 |
| CN101835472A (zh) | 2010-09-15 |
| WO2009061446A1 (en) | 2009-05-14 |
| AR069244A1 (es) | 2010-01-06 |
| ES2436266T3 (es) | 2013-12-30 |
| KR20100075853A (ko) | 2010-07-05 |
| EP2205244B1 (en) | 2013-08-21 |
| CA2696807A1 (en) | 2009-05-14 |
| SI2205244T1 (sl) | 2013-12-31 |
| JP2014221765A (ja) | 2014-11-27 |
| US7968543B2 (en) | 2011-06-28 |
| PT2205244E (pt) | 2013-11-26 |
| AU2008325141B2 (en) | 2014-03-20 |
| MX2010002396A (es) | 2010-04-01 |
| EP2596795A1 (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131083T1 (hr) | POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI | |
| AU2005215775B2 (en) | Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions | |
| DK2596784T3 (en) | Tapentadol compositions | |
| US20090306051A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| US20100029665A1 (en) | Methods and Compositions for Treating Migraine Pain | |
| BRPI0614792A2 (pt) | associação de um agente hipnótico com duração de ação longa e de um agente hipnótico com duração de ação curta e sua aplicação terapêutica | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
| JP2015519329A5 (hr) | ||
| JP2018507243A5 (hr) | ||
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2019516733A5 (hr) | ||
| JP2013518124A5 (hr) | ||
| JP2008534663A (ja) | 慢性的な痛みおよび疲労を特徴とする症候群の治療のためのネフォパムおよびその類似体の使用 | |
| TWI612965B (zh) | 玻尿酸之用途及疼痛抑制用醫藥組成物 | |
| JP2006513184A5 (hr) | ||
| JP2018522920A5 (hr) | ||
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2024517194A (ja) | サイケデリック薬の用量を漸増する方法 | |
| JP2016505050A5 (hr) | ||
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| US20090176857A1 (en) | Use of Organic Compounds |